Christopher Horan's most recent trade in Artiva Biotherapeutics Inc was a trade of 7,002 Common Stock done at an average price of $9.0 . Disclosure was reported to the exchange on May 19, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Artiva Biotherapeutics Inc | Christopher Horan | Chief Tech Operations Officer | Sale of securities on an exchange or to another person at price $ 9.01 per share. | 19 May 2026 | 7,002 | 293,450 | - | 9.0 | 63,073 | Common Stock |
| Artiva Biotherapeutics Inc | Christopher Horan | Chief Tech Operations Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2026 | 117,300 | 302,639 | - | 0 | Common Stock | |
| Artiva Biotherapeutics Inc | Christopher Horan | Chief Tech Operations Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.00 per share. | 15 Feb 2026 | 2,187 | 300,452 | - | 4 | 8,748 | Common Stock |
| Artiva Biotherapeutics Inc | Christopher Horan | Chief Tech Operations Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2025 | 107,156 | 185,339 | - | 0 | Common Stock | |
| Artiva Biotherapeutics Inc | Christopher Horan | Chief Tech Operations Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 12 Dec 2025 | 77,519 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Artiva Biotherapeutics Inc | Christopher Horan | Chief Tech Operations Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 12 Dec 2025 | 20,519 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Artiva Biotherapeutics Inc | Christopher Horan | Chief Tech Operations Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 12 Dec 2025 | 9,119 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Artiva Biotherapeutics Inc | Christopher Horan | Chief Tech Operations Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.25 per share. | 15 Nov 2025 | 1,899 | 78,183 | - | 3.3 | 6,172 | Common Stock |
| Artiva Biotherapeutics Inc | Christopher Horan | Chief Tech Operations Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.75 per share. | 15 May 2025 | 3,577 | 80,082 | - | 2.8 | 9,837 | Common Stock |
| Artiva Biotherapeutics Inc | Christopher Horan | Chief Tech Operations Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.13 per share. | 15 May 2025 | 1,341 | 83,659 | - | 2.1 | 2,856 | Common Stock |
| Artiva Biotherapeutics Inc | Christopher Horan | Chief Tech Operations Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 60,000 | 85,000 | - | 0 | Common Stock | |
| Artiva Biotherapeutics Inc | Christopher Horan | Chief Tech Operations Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2024 | 25,000 | 25,000 | - | 0 | Common Stock |